NEW YORK – The National Cancer Institute said Wednesday that it is soliciting applications for the reissuance of its Clinical Proteomic Tumor Analysis Consortium.
The reissuance will continue the initiative's emphasis on proteogenomic research and will provide up to $11.3 million in 2022 to fund 11 awards, with funding anticipated to continue at a similar level over a total of five years.
The funds will support research at three Proteome Characterization Centers (PCCs), which use proteomic technologies to characterize genomically characterized samples provided by NCI; four Proteogenomic Data Analysis Centers (PGDACs), which will conduct data analysis integrating the proteomic and genomic information collected from the NCI samples; and four Proteogenomic Translational Research Centers (PTRCs), which will focus on exploring the role proteogenomic information can play in understanding drug response and resistance to therapy.
The reissuance marks the fourth stage of the CPTAC initiative and continues the basic structure and proteogenomic focus of the third phase, which launched in 2017 and has received $65 million in funding over the course of five years. CPTAC emerged from the NCI's Clinical Proteomic Technologies for Cancer initiative, which launched in 2006.
Applications for funding are due June 30, 2021.